NCT03107416 - Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 5, 2017

Primary Completion Date

April 5, 2026

Study Completion Date

April 5, 2026

Conditions

Unresectable Hepatocellular Carcinoma

Interventions

PROCEDURE

Hepatic artery embolization (HAE)

The intervention being studied is HAE for the treatment of HCC in combination with Bumetanide. HAE is a standard of care procedure.

DRUG

Bumetanide

Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Consent and follow-up only), Harrison

07920

Memorial Sloan Kettering Basking Ridge (Consent and follow-up only), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Consent and follow-up only), Middletown

07645

Memorial Sloan Kettering Bergen (Consent and follow-up only), Montvale

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER